In a landmark development for neuro-rehabilitation and personal mobility, Paris-based medtech innovator Wandercraft has officially secured US Food and Drug Administration (FDA) clearance for its flagship self-balancing standing exoskeleton, "Eve." This regulatory milestone paves the way for a highly anticipated commercial launch in the United States, scheduled for September 2026.
By bridging the gap between clinical rehabilitation tools and personal, everyday assistive devices, Wandercraft is poised to redefine the quality of life for millions of Americans living with spinal cord injuries (SCI) and other forms of paralysis.
The Core Innovation: Moving Beyond the Wheelchair
For decades, the wheelchair has served as the primary mobility solution for individuals with spinal cord injuries. While essential, prolonged wheelchair use is associated with significant secondary health risks, including pressure ulcers, cardiovascular decline, metabolic issues, and the loss of bone density. Wandercraft’s Eve exoskeleton is designed not to replace the wheelchair, but to augment it, providing users with the ability to stand and move upright in their own environments.
Engineering the Future of Gait
Eve represents the culmination of years of R&D, building directly upon the success of the company’s "Atalante X" device, which has already been deployed in over 150 rehabilitation and research facilities globally. Unlike earlier generations of exoskeletons that often required cumbersome crutches or constant manual input, Eve utilizes sophisticated motorized joints paired with proprietary stabilization algorithms. These algorithms autonomously manage the complex balancing dictates required for human upright movement.
Users interact with the device via a handheld controller, which allows them to guide their directional movement with precision. This intuitive interface enables a level of autonomy that was previously unattainable for many users with varying degrees of lower-limb impairment.
A Chronology of Progress
The path to FDA clearance for Eve has been a calculated, multi-year journey defined by rigorous clinical validation and strategic financial planning.
- 2012–2024 (Foundation & Clinical Validation): Wandercraft focuses on the development of Atalante X, establishing a gold standard for gait rehabilitation in European and international clinics. The data gathered from thousands of hours of clinical use informs the development of the personal-use device, Eve.
- June 2025 (Financial Runway): The company secures a critical $75 million Series D financing round. This influx of capital provides the necessary resources to navigate the final stages of FDA review and build the supply chain infrastructure required for a US market entry.
- March 2025: The broader exoskeleton market sees increased activity as competitors like ReWalk receive FDA clearance for their seventh-generation devices, highlighting the competitive, yet growing, nature of the sector.
- August 2026: Wandercraft receives official FDA clearance for Eve, verifying the device’s safety and efficacy for personal use.
- September 2026: The scheduled US commercial launch.
Supporting Data: Clinical Trials and Patient Outcomes
The FDA’s decision was underpinned by a comprehensive, three-site clinical trial that examined the device’s safety, functional utility, and real-world readiness. Participants with a wide spectrum of spinal cord injury severities were put through structured training modules to ensure they could safely operate the exoskeleton in daily life.
Beyond Mobility: Holistic Health Improvements
The clinical data revealed that the benefits of using Eve extend far beyond the act of walking. Participants reported significant improvements across several health metrics:
- Psychological Well-being: Patients reported higher levels of confidence and reduced symptoms of depression.
- Physiological Gains: Improvements were noted in lower-limb spasticity, sitting balance, and overall endurance.
- Systemic Health: Some trial participants observed better sleep quality and, crucially, improvements in bowel and bladder function—common pain points for those with long-term spinal cord injuries.
"What makes these findings meaningful is that the technology was evaluated not only on engineering performance but also on how users and companions could safely integrate it into real-world activities," noted Gail Forrest, director of the Tim and Caroline Reynolds Center for Spinal Stimulation at the Kessler Foundation, one of the primary trial sites.
Official Responses and Industry Leadership
The industry response to the clearance has been overwhelmingly positive, signaling a shift in how medical devices are perceived by both insurers and clinicians.
The CEO’s Vision
Matthieu Masselin, CEO of Wandercraft, underscored the gravity of this achievement in a recent statement: "FDA clearance of Eve marks one of the most important moments in Wandercraft’s history and a significant step for the people, families, clinicians, researchers, and partners who helped make it possible."
Strategic Preparation for Launch
Recognizing that technology is only as effective as the support system surrounding it, Wandercraft has proactively established partnerships with key rehabilitation and complex rehabilitation technology (CRT) providers. By collaborating with organizations like New York-based Walk US and Pennsylvania’s Good Shepherd Rehabilitation, the company aims to ensure that clinicians are fully trained and that patients have a seamless pathway from evaluation to personal ownership.
Implications: Accessibility and the Economic Landscape
The launch of Eve arrives at a critical juncture for the US healthcare system. With over five million Americans currently living with some form of paralysis, the need for advanced assistive technology has never been greater.
The Role of Medicare
One of the most significant barriers to the adoption of advanced medical exoskeletons has historically been cost. However, the landscape for reimbursement is evolving. As of 2024, Medicare provides a clear reimbursement pathway for eligible personal exoskeleton users under the Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) program, specifically under billing code K1007. This institutional support is expected to be a major catalyst for the widespread adoption of devices like Eve.
A Competitive Market
The exoskeleton sector is maturing rapidly. While ReWalk remains a prominent player with its ReWalk 7 device, the market is no longer a monopoly. The introduction of Wandercraft’s Eve increases the diversity of options available to patients, fostering a competitive environment that typically leads to faster innovation, better user interfaces, and more refined safety features.
Conclusion: The Road Ahead
As the September 2026 launch date approaches, the focus for Wandercraft shifts to scaling production and broadening its network of provider partners. The potential for the Eve exoskeleton to fundamentally alter the day-to-day experience of those with paralysis cannot be overstated. By enabling users to stand, move, and navigate their world on their own terms, Wandercraft is not just selling a device—it is delivering a restored sense of agency.
For the clinicians, engineers, and, most importantly, the patients who have participated in this long-term endeavor, the FDA clearance is a vindication of years of hard work. As we look toward the future, the integration of robotics into the personal lives of those with physical disabilities appears not just as a possibility, but as an inevitable and welcome standard of care.
About the Author
